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Abstract
We isolated a clonal cell line (4E) from kidneys of mice expressing green fluorescent protein
controlled by the endothelial-specific Tie2 promoter. When grown in a three-dimensional matrigel
matrix they formed a fluorescent capillary network. In vivo angiogenesis assays using growth factor-
depleted matrigel implanted plugs promoted a moderate angiogenesis of host endothelial cells. Using
vascular endothelial growth factor (VEGF)-A and fibroblast growth factor-2 in the plugs containing
4E-cells resulted in a robust vasculogenesis. Transplantation of 4E cells into mice with acute renal
ischemia showed selective engraftment in the ischemic kidney which promoted tubular regeneration
by increasing epithelial proliferation and inhibiting apoptosis. This resulted in an accelerated
functional recovery 3 days after ischemia. These mice showed a 5-fold increase in tissue VEGF
expression compared to controls, but no difference in plasma VEGF level corresponding with better
preservation of peritubular capillaries, perhaps due to a local paracrine effect following systemic 4E
infusion. One month after ischemia, 9% of engrafted 4E cells expressed green fluorescent protein in
the peritubular region while half of them expressed α-smooth muscle actin. Our study shows that
kidney mesenchymal stem cells are capable of differentiation toward endothelial and smooth muscle
cell lineages in vitro and in vivo, support new blood vessel formation in favorable conditions and
promote functional recovery of an ischemic kidney.
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Sinusoidal endothelium in bone marrow and extraosseous capillaries represent a large
disseminated niche for mesenchymal stem cells (MSC), which are present, according to the
recent study, in practically all postnatal organs and tissues tested.1 This disseminated pool of
MSC localized to the basement membrane of blood vessels in close contact with the vascular
endothelium may be involved in the local regulation of vascular and/or tissue regeneration.
Whereas osteoblastic bone marrow niche provides microenvironment supportive of stem cell
quiescence, the vascular niche facilitates their proliferation, differentiation, and rapid
mobilization.2 These perivascular stem cells are, in part, represented by pericyte-like MSCs
also termed mural stem cells.1 MSCs have the potential to differentiate along multiple lineages
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in vitro, including the best characterized osteogenic, chondrogenic, and adipogenic
differentiation,3,4 although, according to the recent data, these cells can differentiate toward
endothelial cell lineage.5–8 The latter claim rests on the use of bone marrow-derived MSC in
a canine model of chronic cardiac ischemia in which MSCs were found to be colocalized with
endothelial and smooth muscle cells, but not with cardiomyocytes, 1 month after
transplantation. This was associated with a trend toward reduced fibrosis and increased
vascular density. Weekly injections of MSC in collagen4A3-deficient mice, a model of Alport
syndrome, resulted in the reduction of renal fibrosis and prevention of the loss of peritubular
capillaries in conjunction with the localization of transplanted cells in peritubular capillaries.
9 Conflicting results demonstrating no morphologic improvement after MSC transplantation,
as opposed to therapeutic efficacy of transplanting bone marrow-derived cells, in the model
have been reported by Prodromidi et al.10 An account on the differentiation of isolated bone
marrow-derived MSC cultured in a medium containing vascular endothelial growth factor into
endothelial cells in vitro has been published by Oswald et al.11 and Togel et al.12 The apparent
paucity of data on the differentiation potential of MSC toward endothelial lineage, especially
in vivo, and the absence of published data on organ-derived MSC prompted us to investigate
these issues. Our main goal was to elucidate the possible differentiation repertoire of local
MSC and their contribution to tissue protection. Specifically, this study was designed to address
this possibility both in vitro and in vivo. Using a clonal cell line of MSC (4E) isolated from the
kidney of adult Tie-2 green fluorescent protein (GFP) transgenic FVB/NJ mice,8 we examined
their in vitro and in vivo angiogenic and vasculogenic properties and further tested their
differentiation potential in mice with acute ischemic renal injury.
RESULTS
In vitro angiogenesis
To examine the possibility that MSC can differentiate toward endothelial lineage, we tested
their in vitro angiogenic potential using 4E cells. These cells were cloned from a single colony
of the original MSC isolated from the kidney of Tie-2/GFP mice and thoroughly characterized,
8 thus negating any contamination with endothelial cells. As illustrated in Figure 1a, when
cultured on three-dimensional matrigel in EGM-2 medium, 4E cells initially formed ‘sphere’-
like structures, which gradually spread out forming a dense capillary network. Some cells in
these capillaries showed positive GFP signals. Fluorescence-activated cell sorter analysis of
isolated capillary-forming cells cultured for 30 days indicated that about 14.8% were double
positive for GFP/CD31 (under matrigel/EGM-2 medium culture conditions) as opposed to the
original 4E MSC population negative for these markers (Figure 1b). When cultured in EGM-2
or MSC culture medium, 4E cells displayed scattered appearance of endothelial (Tie2-GFP)
and α-smooth muscle actin (αSMA) cell markers (Figure 1c), revealing the alternative
acquisition of either the endothelial or the smooth muscle cell phenotypical markers depending
on the ambient conditions, namely EGM-2 or MSC medium, respectively.
In vivo neovascularization of angioreactors
We next studied the angiogenic and/or vasculogenic potential of kidney MSC (4E cells) in
vivo using matrigel-filled implantable angioreactors (directed in vivo angiogenesis assay).
Control angioreactors, which contained only growth factor-depleted matrigel, revealed no
capillary ingrowth. Second control group, angioreactors containing growth factors only,
showed a robust ingrowth of host capillaries. The 4E-containing angioreactors, within 15 days
of implantation, showed an intense angiogenesis originating from the host endothelial cells
and a modest vasculogenesis (Figure 2). These neovessels were apparently patent and
functional, as they were stained positive for Lycopersicon Esculentum lectin (LEL)-FITC,
administered before harvesting the subcutaneously implanted angioreactors. Considering the
fact that majority of neovessels originated from the host endothelium, these results are
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consistent with the paracrine signaling hypothesis.8 The 4E cells promoted the in vivo
angiogenesis, presumably, through the secretion of pro-angiogenic factors and chemoattraction
of the host endothelial cells.
When growth factors, vascular endothelial growth factor-A/fibroblast growth factor-2 (VEGF-
A/FGF-2), were added to the 4E-containing matrigel angioreactors, a robust neovascularization
occurred, in which functional (LEL-FITC-positive) vascular network was formed. We
documented that the CM-DiI-labeled 4E cells were recruited into the neovasculature, when the
exogenous growth factors were presented. The number of the capillary-associated 4E cells was
significantly higher in the growth factor-containing group (57.46 ± 7.15%) compared with the
4E growth factor-free angioreactors (8.54 ± 3.01%) (Figure 2, inset). The high-magnification
images of the neovasculature in Figure 2 (right panel) illustrate that, in the growth factor-
containing matrigel, the majority of CM-DiI-labeled 4E cells recruited to the vessels were also
GFP-positive, suggesting that these capillaries were formed through vasculogenesis,
specifically via the differentiation of 4E cells to endothelial cells. This green fluorescent signal
could be attributed to either Tie2-GFP or LEL-FITC (readily distinguishable due to the
cytosolic vs luminal membrane fluorescence, respectively). However, even a potential overlap
in signals would not hinder the interpretation of the results as either staining originated from
endothelial cells. Furthermore, ultrathin deconvoluted fluorescent microscopy analysis
confirmed that some of the cells incorporated into the neovasculature in the growth factor-
containing matrigel were CM-DiI and LEL-FITC double-positive (Figure 3). Thus, in the
absence of VEGF-A/FGF-2, 4E cells support angiogenesis by promoting the host endothelial
cell infiltration of angioreactors, whereas in the presence of these growth factors, 4E cells
transdifferentiate into endothelial cells and participate in vasculogenesis.
Transplantation of 4E cells in acute renal ischemia: transdifferentiation to endothelial or
αSMA-expressing cells
Next, we addressed the possibility of 4E cell participation in vasculogenesis associated with
tissue injury. Toward this end, we studied the pro-angiogenic and renoprotective potential of
4E cells using acute renal ischemia–reperfusion (I/R) model. We first examined the
engraftment of the CM-DiI-labeled 4E cells in the ischemic kidney 3–30 days after
transplantation (Figure 4). The number of the engrafted CM-DiI-labeled 4E cells was
significantly higher in the ischemic kidney compared with the contralateral non-ischemic
kidney 3 days after transplantation (1.9 ± 0.1 vs 0.2 ± 0.1 cells per mm2, respectively, P <
0.01). This difference in 4E cell engraftment to ischemic and contralateral non-clamped kidney
was maintained up to 30 days (Figure 4b). Tie2-GFP signal was not detectable in kidney
sections at 3–15 days after I/R injury. In contrast, by 30 days after I/R injury, 9.2 ± 3.1% of
engrafted 4E cells expressed Tie2-GFP along the peritubular capillary area, suggesting a
possible endothelial transdifferentiation of MSC (Figure 4c). In addition, the examination of
the αSMA expression indicated that about 45 ± 6–55 ± 1% of the engrafted 4E cells became
αSMA-positive 15–30 days after I/R injury (Figure 5).
In the next series of experiments, we examined functional consequences of 4E cell
transplantation in mice with bilateral I/R injury. Thirty minutes of bilateral ischemia induced
severe renal dysfunction as judged by a significant increase in plasma creatinine levels (Figure
6a): from the baseline of 0.24 ± 0.07 to 1.92 ± 0.22 mg per 100 ml 1 day after clamping.
Compared with control ischemic mice, animals that received 4E cells after I/R injury had a
significantly lower plasma creatinine levels 2–3 days after ischemic injury (24–48 h after cell
transplantation), suggesting an early renoprotection afforded by the transplanted cells. To
obtain insights into the mechanism of 4E-mediated renoprotection in I/R injury, we examined
the rates of tubular epithelial cell (TEC) proliferation and apoptosis in the kidneys of control
and 4E-transplanted mice. As shown in Figures 4e and 6c, transplantation significantly
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increased the number of proliferating Ki-67-positive TEC (255 ± 22 vs 135 ± 16 cells per
mm2, respectively, P < 0.05) and simultaneously reduced the number of apoptotic TEC on
TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay (58
± 7 vs 117 ± 13 cells per mm2, respectively, P < 0.05). At 15 and 30 days post-ischemia, the
level of plasma creatinine was similar in both groups and indistinguishable from the baseline
(data not shown).
To further assess the role of 4E cells in renoprotection, microvascular density and the degree
of fibrosis were examined in ischemic and control kidney sections processed for the expression
of CD31 and stained with Masson’s trichrome stain. As summarized in Figure 7, the degree
of microvascular rarefaction was significantly reduced in 4E-transplanted vs control kidneys
at early (3 days) time points after ischemia, but later these differences disappeared. Trichrome
staining revealed comparable levels of fibrosis between transplanted and control post-ischemic
kidneys at day 30 (1.3 ± 0.3 vs 1.6 ± 0.3 in cortex and 1.4 ± 0.3 vs 1.9 ± 0.4 in medulla,
respectively). Plasma and renal tissue levels of pro- and anti-inflammatory cytokines, such as
TNF-α, IL-1α, IL-β, IL-6, KC, and IL-10, did not show significant difference between control
and 4E-transplanted mice (data not shown). However, compared with control, 4E-transplanted
mice showed a fivefold increase in renal tissue VEGF expression at 3 days after I/R injury
(Figure 7d). In contrast, the plasma VEGF level did not show any significant difference between
the two groups (9.5 ± 1.3 vs 9.4 ± 2.4 pg/ml). These data indicated that the fact that 4E cells-
afforded renoprotection is, in part, due to the local VEGF paracrine effect, resulting in the
preservation of peritubular capillaries, reduced apoptosis, and increased proliferation of TEC.
DISCUSSION
The focus of this study was on the potential of a kidney-derived MSC line, 4E cells previously
obtained and characterized by us,8 to differentiate toward endothelial lineage, both in vitro and
in vivo, and their contribution to organ repair after ischemic injury. Previous studies have shown
that MSCs isolated mainly from the bone marrow, as well as various adult tissues, are
clonogenic, plastic-adherent, multipotent cells capable of differentiating in vitro to a variety
of cell lineages, including adipocytes, osteoblasts, chondrocytes, myoblasts, neural tissue, and
endothelial cells.4,13–18 These unique properties have implicated MSC as promising
candidates for cell-based therapy in the treatment of a range of chronic, degenerative, and
ischemic diseases.19 Benefits of MSC transplantation were demonstrated in clinical trials 20
and various animal experiments,21,22 but the underlying mechanisms remain elusive. With
regard to the ischemic disease, it has been shown that transplantation of stem or progenitor
cells can improve neovascularization and recovery of ischemic tissue and organ.23,24 The
following four hypotheses currently ascribe this regenerative mechanisms to: (a) engraftment
and differentiation of the administered cells into the cellular components of the host tissue or
organ;23,25 (b) therapeutic fusion with the existing host cells;4,26–28 (c) release of paracrine
signals from the administered cells;29 and (d) stimulation of endogenous repair through the
regeneration of stem cell niches in the local tissue.30 The in vitro findings presented herein
appeared to highlight an additional mechanism, that is, vasculogenic potential of MSC.
Focusing on the angiogenesis and ischemic disease, the data presented provide three
independent lines of evidence demonstrating the angiogenic and vasculogenic potential of 4E
cells: (1) in vitro transdifferentiation to endothelial-like and smooth muscle-like cells; (2) in
vivo neovascularization of angioreactors; and (3) in vivo engraftment and transdifferentiation
toward endothelial lineage after acute ischemic renal injury. Our data clearly demonstrate the
propensity of MSC toward endothelial differentiation, as well as paracrine angiogenic
chemoattraction.
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It has been suggested previously that MSC may be one of the sources for circulating endothelial
progenitor cells.4,31 Under certain conditions, they can also directly differentiate to endothelial
cells.11 Our previous data showed that 4E clone of MSC isolated from the kidney secrete
angiogenic factors in culture and support endothelial cell growth and angiogenesis.8 Our in
vivo angioreactor experiments with 4E cells are consistent with this notion, and hence support
the paracrine mechanism of angiogenesis stimulated by MSC. Furthermore, our experiments
also demonstrate an in vivo differentiation of 4E cells to the endothelial cells. In a sharp contrast
to the rarely detected 4E cells when cultured in the growth factor-depleted matrigel, once
VEGF-A/FGF-2 is present, 4E cells show signs of robust recruitment to and endothelial
differentiation in the neovasculature. It is well-known that stem cell engraftment and
endothelial differentiation are growth factor-dependent processes highly dependent on
microenvironmental cues.32 This is further emphasized by the fact that in the absence of added
growth factors to angioreactors, multiple capillaries are formed in spite of only sporadic
incorporation of 4E cells into the functional neovessels (angiogenesis originating from the host
vessels), whereas in the presence of growth factors 4E cells formed new vessels (vasculogenesis
originating from implanted 4E cells).
In a previous study involving tumor angiogenesis, subcutaneous co-injection of bone marrow
MSC with U-87 glioma cells in nude mice resulted in the formation of highly vascularized
tumors.33 In addition to the regulation through paracrine mechanism, it was documented that
bone marrow MSC can be differentiated into CD31-positive cells, which constitute about 5%
of the neovasculature of the solid tumor. Our experiments show that a significant proportion
of 4E cells in the vicinity of the neovasculature were recruited into the vascular wall and
differentiated into endothelial cells once VEGF/FGF was provided.
One of the characteristics of MSC is their ability to home to the sites of tissue damage or
inflammation.34 Using acute renal ischemia model, we observed significantly higher
engraftment of the transplanted 4E cells in the ischemic kidney compared with the non-
ischemic contralateral control at all tested time points over 1 month experimental period. These
data support the concept that stem cell engraftment is highly dependent on local
microenvironmental cues. Indeed, the 4E cells express CXCR48 and upregulated renal SDF-1
signals after ischemic injury may have contributed to their preferential homing and
engraftment. This ability of MSC to home to the sites of acute tissue injury has also been
demonstrated in the settings of bone fracture,34,35 cerebral ischemia,36 as well as the infarcted
myocardium.37
Because (a) there are no consistently reliable markers of these cells in situ and (b) a few
available markers of these cells may disappear after cell differentiation, the strategy we elected
was to isolate and expand clonal 4E MSC ex vivo and transfuse them in vivo as a surrogate for
a behavior of the resident cells. Compared with the acquisition of endothelial lineage markers
in both the in vitro cell culture and the in vivo angioreactor experiments, the endothelial
transdifferentiation rate in our ischemic renal injury experiments is less robust: only 9% of the
engrafted CM-DiI-labeled 4E cells in the ischemic kidney become Tie2-GFP-positive 30 days
after transplantation, indicating their endothelial transdifferentiation. In comparison, the
percentage of the engrafted 4E cells that become αSMA-positive 15–30 days after
transplantation is higher. I/R injury can induce a wide range of gene expression including
VEGF in the kidney.38 These factors may orchestrate the observed 4E-to-endothelial or 4E-
to-smooth muscle cell lineage transdifferentiation in the ischemic kidney. One could speculate
that the composition of the post-ischemic microenvironment may be less favorable for 4E-to-
endothelial transdifferentiation than the conditions found in our cell culture and angioreactor
experiments. Nonetheless, the functional assessment of the ischemic kidney points out to the
amelioration of renal dysfunction 2–3 days after ischemic episode by the 4E cell transplantation
as judged by the plasma creatinine level. It is clear that the observed accelerated functional
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improvement is unrelated to 4E cell transdifferentiation to the endothelial cells because the
renoprotective effect occurs 24–48 h after 4E cell transplantation, as opposed to the much
delayed transdifferentiation. One possible explanation for the early benefits of 4E cell delivery
in the context of recovery from acute renal injury is the previously described paracrine
mechanism.12,18,39 Indeed, 4E cell transplantation was associated with increased proliferation
and reduced apoptosis of TECs. Moreover, microvascular rarefaction in the post-ischemic
kidney was significantly reduced in the 4E-transplanted ischemic group, in synchrony with a
fivefold increase in the renal expression of VEGF, in the absence of changes in systemic VEGF
level. All this argues in favor of a local paracrine effect of 4E cell transplantation. In this regard,
our data are in agreement with results obtained by Togel et al.18 On the other hand, the
transdifferentiation potential toward the smooth muscle/myofibroblastic lineage may represent
the mechanistic explanation for the long-term pro-fibrotic sequelae reported in renal ischemia.
40 It is quite possible that the proportion of MSC transdifferentiating toward the endothelial vs
myofibroblastic lineage is an important determinant of the outcome of renal ischemia.
In summary, kidney-derived MSCs (4E cells) are vasculogenic as demonstrated by the analysis
of implanted matrigel angioreactors supplemented with VEGF-A/FGF-2 growth factors.
Despite this, in the context of acute ischemic injury, the transplantation of kidney-derived MSC
(4E cell) affords renoprotection not through vasculogenesis, but rather through local paracrine
effects that promote renal regeneration and prevent microvascular dropout.
MATERIALS AND METHODS
Animal studies
The animal study protocol was in accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee. Adult (8–20 weeks old) Tie-2/GFP mice41 (FVB/NJ strain) were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA). As the expression of GFP
protein is under the control of Tie2 gene promoter/enhancer elements, it is hence present in
virtually all endothelial cells where the Tie2 gene is constitutively expressed. This mouse model
provided a convenient tool for monitoring the endothelial differentiation process. Animals were
kept under temperature-controlled conditions of 12-h light/dark cycle, with water and food ad
libitum. A separate group of mice was used as hosts of angiogenic cylinders (angioreactors)
implanted subcutaneously as detailed below. Prior to the killing, mice were anesthetized with
a combination of ketamine and xylazine and received intraperitoneal injection of 250 U/kg of
heparin. Blood was collected from the left ventricle, and animals were flushed with 40 ml
phosphate-buffered saline (PBS).
Isolation and culture of MSC–4E cells
Using a technique for culturing multipotent mesenchymal cells from adult tissues,1,42 we have
previously isolated and cloned fibroblast-like cell line (referred to as 4E) from the kidney of
adult Tie-2/GFP mouse. These 4E cells could be differentiated along multiple mesodermal
lineages, including adipocytes, osteoblasts, as well as endothelial cells. Analysis of the
expression of surface antigens, growth factor receptors, cytoskeletal proteins, and transcription
factors revealed a pattern that was compatible with both mouse MSCs and renal stromal
progenitor cells.8 4E cells were maintained on gelatin-coated dishes in minimum essential
medium (MEM) with 10% horse serum (Gem Biotech, Woodland, CA, USA) and consistently
expressed the above markers between passages 10 and 25.
Flow cytometry analysis
Expression of GFP and staining of CD31 with phycoerythrin-conjugated antibody (BD
Biosciences, Rockville, MD, USA) on the 4E cells following 1 month of three-dimensional
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matrigel culture were measured using fluorescence-activated cell sorting as previously
described.8 Each analysis included at least 10,000 events and was performed on at least two
separate cell preparations.
In vitro angiogenesis assay
Cultured 4E cells were detached with trypsin/EDTA, viable cells counted, and single-cell
suspension (at a density of 2 × 105 cells per ml) was prepared using EGM-2 medium (Clonetics,
San Diego, CA, USA) or MSC culture medium. A volume of 200 μl per well of growth factor-
depleted, phenol red-free Matrigel (BD Biosciences, San Jose, CA, USA) was plated in four-
well chamber slides (BD Biosciences) and incubated at 37 °C for 15 min. The same volume
(200 μl) of cell suspension was plated on Matrigel. For comparison, the same amount of cells
was also plated on chamber slides that were pre-coated overnight with fibronectin (BD
Biosciences) at 4 °C. Endothelial capillary formation and the GFP signal were monitored using
an inverted fluorescence microscope every 3 days over 1 month period. By the end of
observations, the cells were washed with PBS and stained with phycoerythrin-labeled anti-
mouse CD31 (PECAM-1, BD Biosciences) or α-SMA antibody (Dako North American,
Carpinteria, CA, USA) with appropriate phycoerythrin-conjugated secondary antibody
applied. After repeated washes with PBS, the chamber slides were examined and images
obtained using Nikon fluorescent microscope (Eclipse TE2000-U) equipped with a digital
camera (Spot model 4.2; Diagnostic Instruments, Sterling Heights, MI, USA).
In vivo angiogenesis and vasculogenesis studies using angioreactors
The directed in vivo angiogenesis assay was adapted for our in vivo angiogenesis study.
Matrigel filling and cylinder implantation procedure were conducted under sterile conditions
following the previously published protocol43 and the manufacturer’s instructions (Trevigen
Inc., Gaithersburg, MD, USA). In brief, the sterile implant-grade silicone cylinders, referred
to as angioreactors, were filled at 4 °C with 20 μl of matrigel containing FGF-2 (3.75 ng),
VEGF-A (1.25 ng), and heparin (200 ng) with or without admixed 4E. The 4E cells were labeled
with red fluorescent cell tracker CM-DiI (Molecular Probes, Eugene, OR, USA) and mixed
with the matrigel at a density of 3000 cells per angioreactor. Cylinders were then incubated at
37 °C for 1 h to allow gel formation, and implanted subcutaneously into the dorsal flank of
FVB mice. For each implantation experiment, four types of angioreactors were prepared:
matrigel or growth factor alone, 4E/matrigel alone, and 4E/matrigel with VEGF-A/FGF-2.
Fifteen days after implantation, angioreactors were harvested from the host mice. To visualize
the ingrowth of the neovasculature from the host mice, 5 min before killing 100 μl of LEL-
FITC (1 mg/ml in 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 150
mM NaCl, pH 7.5; Sigma, St Louis, MO, USA) was injected via tail vein to label the patent
systemic vascular endothelium of the host mice. The collected angioreactors were fixed in 4%
paraformaldehyde in PBS overnight at room temperature. The sealed bottom portion of the
angioreactor was trimmed away with scissors. The fixed matrigel plugs were carefully
removed. After washing with PBS, the gel plugs were whole mounted on chamber slides in
glycerol/PBS and gently flattened under the coverslip. The slides were examined and images
captured under a fluorescence microscope (Nikon) or confocal microscope (Zeiss Aniovert
200 inverted fluorescence microscope equipped with Zeiss Axiocam digital camera, Carl Zeiss,
Hamburg, Mecklerburg, Germany) for deconvolution analysis. Z-stack images at 0.5 μm per
step were collected using × 10 fluorescence objective lens and analyzed with Axiovision 4.4
software.
Transplantation of 4E cells in a model of renal ischemia
Unilateral or bilateral renal ischemia in male FVB/NJ mice (aged 8–20 weeks) was performed
according to previously detailed protocol.8 Briefly, mice were anesthetized, a midline
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laparotomy and bilateral or unilateral renal pedicle clamping was performed with
microserrefines (Fine Science Tools, Foster City, CA, USA). The abdomen was covered with
gauze moistened in PBS, and throughout the ischemia period, animals were kept well hydrated
with saline and at a constant temperature (~37 °C) using a heated thermoplate (Tokai Hit,
Fujinomiya-shi, Shizuoka-ken, Japan). After 30 min of ischemia, the clamps were removed,
and reperfusion was confirmed visually. CM-DiI-labeled 4E cells (106 cells per animal) were
injected intravenously via tail vein 24 h after reperfusion. Mice were killed at different time
points between 1 and 30 days after renal I/R injury, blood samples were obtained and kidneys
removed for further analyses. Plasma creatinine concentration was determined using a
colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s
protocol.
Immunofluorescent and immunohistochemical analysis
Kidneys were fixed in 4% paraformaldehyde overnight at 4 °C, transferred to PBS containing
30% sucrose (overnight at 4 °C), embedded in OCT (Tissue Tek; Sakura Finetek, Torrance,
CA, USA) and stored at −80 °C until analysis. Cryosections (10–20 μm) were used for
immunofluorescent and immunohistochemical analysis. The identification of engrafted
transplanted 4E cells was done by detecting red fluorescent CM-DiI-labeled cells and the
presence of GFP signal by fluorescence microscopy of kidney sections. To detect the
expression of αSMA, sections were stained with mouse monoclonal anti-αSMA (1:250, Dako,
Carpinteria, CA, USA), and tubular cell proliferation in the post-ischemic kidney was identified
by staining sections with rabbit anti-Ki-67 polyclonal antibody (Abcam, Cambridge, MA,
USA; 1:50). TUNEL assay using an In Situ Cell Death Detection Kit, TMR red (Roche,
Indianapolis, IN, USA) was used to detect tubular cell apoptosis in post-ischemic kidney.
Sections were screened for positive nuclei under a fluorescence microscope, and 20 random
fields in the corticomedullary area were counted for every kidney at × 40 magnification.
Staining for peritubular capillary endothelial cells was performed on 20 μm cryosections.
Briefly, endogenous peroxidase activity and nonspecific binding were blocked, and sections
were incubated overnight at 4 °C with rat anti-mouse CD31 antibody (MEC 13.3, BD
Biosciences, 1:50), followed by incubation at room temperature with peroxidase-conjugated
donkey anti-rat antibody (1:200, Jackson ImmunoResearch, West Grove, PA, USA) and
chromogenic substrate 3,3′-diaminobenzidine (Dako). The sections were counter-stained with
hematoxylin and mounted. Negative control received similar treatment with omission of the
primary antibodies. Quantification of peritubular capillary loss was performed by calculating
the rarefaction index as described.44 The CD31-immunostained sections were examined
through 10 × 10 grid under a × 40 objective. Each square within the grid that did not contain
CD31-positive capillary was counted. At least 20 fields in the cortex and outer medulla were
examined on the cross-section of each kidney, and a mean score per section was calculated.
This scoring system, thus, inversely reflects peritubular capillary rarefaction, whereby low
values represent intact capillaries and higher values indicate loss of capillaries (minimum
possible capillary score is 0, and the maximum score is 100). The interstitial fibrosis was
assessed with Masson’s trichrome staining at low-power view (× 150) and scored by an
investigator blinded to the experimental design using a semi-quantitative scale (0, absent; 1,
<25% of specimen area; 2, 25–50% of specimen area; 3, >50% of specimen area).
Renal tissue and plasma cytokine measurements
Snap-frozen decapsulated kidneys were lysed with RIPA buffer (1 × PBS, 1% Nonidet P-40,
0.5% sodium deoxylate, 0.1% SDS, and protease inhibitor), homogenized, and incubated at 4
°C for 30 min. Homogenates were subsequently centrifuged at 1500 g at 4 °C for 15 min, and
supernatants and plasma were stored at −80 °C until assays were performed. Multiplexed
cytokine measurements for renal tissue homogenates and plasma were performed using
multiplex assay kit (MCYTO-70K-13, Millipore, St Charles, MO, USA), which allowed the
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simultaneous quantification of the following analytes: TNF-α (Tumor Necrosis Factor α),
Interleukin (IL)-1α, IL-β, IL-6, KC, and IL-10. VEGF was measured using mouse single-plex
VEGF Beadmates (46–196; Millipore). All analytes were tested individually and in
combination to ensure that there were no cross-reactions. All measurements were performed
in duplicate. The plates were analyzed using Luminex IS100 analyzer (Luminex Inc., Austin,
TX, USA). The data were saved and evaluated as median fluorescence intensity (MFI) using
appropriate curve-fitting software (Luminex 100IS software version 2.3). A five-parameter
logistic method with weighting was used. Cytokine and VEGF levels were corrected for the
amount of protein present using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules,
CA, USA) with IgG as standard.
Statistical analysis
Data are expressed as mean ± s.e.m. Differences between the groups were analyzed by analysis
of variance or the Kruskal–Wallis test using SPSS 11.0 (SPSS, Chicago, IL, USA). A P-value
less than 0.05 was considered statistically significant.
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Figure 1. In vitro differentiation of 4E cells into endothelial- and smooth muscle-like cells
(a) The 4E initially formed ‘sphere’-like structure that gradually spread out forming numerous
capillaries. Acquisition of GFP + signal by these cells and their morphology are illustrated.
(b) FASC analysis of 4E cells maintained in MSC culture medium showed the absence of GFP/
CD31 double-positive cells, further confirming that these cells initially did not contain
endothelial cells (left panel). However, when 4E cells were cultured for 30 days in matrigel/
EGM-2 medium, 14.8% cells were GFP/CD31 double-positive (right panel), whereas only
3.65% became double positive in fibronectin/EGM-2 medium (middle panel). (c) The 4E cells
differentiated into smooth muscle-like cells expressing αSMA, but not Tie2-GFP, when
cultured in MSC medium (upper panel). In contrast, 4E cells differentiated into endothelial-
like cells expressing Tie2-GFP, but not αSMA, when cultured on matrigel in EGM-2 medium
(c).
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Figure 2. In vivo contribution of 4E cells to neovascularization of angioreactors
Fifteen days after subcutaneous implantation of angioreactors, 4E cells promoted the invasion
of endothelial cell ingrowth into the matrigel. The neovasculature appears functional as vessels
are lectin-FITC-positive. With the addition of VEGF/FGF, the functional neovasculature
showed signs of more vigorous growth and mature architecture, and the engraftment of 4E into
the vascular wall was dramatically enhanced. Many of the engrafting 4E cells were green
fluorescence-positive, reflecting their endothelial differentiation indicated by either one or both
of the events, the expression of Tie2-GFP or/and Lycopersicon Esculentum lectin-FITC (LEL-
FITC) staining. The high-magnification images are inserted on the right panel and show the
framed area. Growth factor (GF)-depleted matrigel alone did not support any visible invasion
of endothelial cells or ingrowth of capillaries. The 4E cells were pre-labeled with cell tracker
CM-DiI (red fluorescence).
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Figure 3. In vivo contribution of 4E cells to neovascularization
To better visualize the participation of 4E cells in the neovascularization, angioreactors were
also analyzed using deconvolution microscopy. Images on the left represent consecutive
fluorescence microscopy of the LEL-FITC and CM-DiI-labeled cells as well as the merged
image. The image on the right (top panel) shows a three-dimensional reconstruction of the
angioreactor, representing stacks of frames spanning 40 μm in thickness. The double-positive
cell in the cross of the vertical and horizontal lines is indicated by the arrows in the cross-
sectional X- and Y-view strips. The image in the lower right panel shows an enlarged area
framed in the merged image.
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Figure 4. Analysis of the engraftment and transdifferentiation of transplanted 4E cells after I/R
injury
The number of engrafted CM-DiI-labeled 4E cells in peritubular capillaries of the unilateral
ischemic kidney was compared with the contralateral non-ischemic control 3, 15, and 30 days
after I/R injury. (a) Representative images of red fluorescent CM-DiI-labeled 4E cells (arrow)
and Tie2-GFP fluorescence of kidneys at different times after ischemia. (b) The summary of
quantitative analysis of engrafted cells and the appearance of GFP fluorescence. (c) After 30
days, 9.2 ± 3.1% of the engrafted CM-DiI-labeled cells become Tie2-GFP-positive. Arrows
indicate CM-DiI- and/or GFP-expressing cells. Nuclei were stained with DAPI. Original
magnification was × 600. *P < 0.05 vs control. n = 6 mice for each group, values are mean ±
s.e.m.
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Figure 5. Immunofluorescence analysis of the expression of αSMA in engrafted 4E cells in ischemic
kidney
(a–c) Representative images of CM-DiI- and/or αSMA-expressing 4E cell engrafting ischemic
kidneys (merged image shown in panel c with the nuclear DAPI staining) 30 days after I/R
injury. (d) Quantitative analysis of results at 3–30 days after I/R injury. Original magnification
was × 400. *P < 0.01 vs 3 days. n = 4 in each group, values are mean ± s.e.m.
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Figure 6. Accelerated renal functional recovery by 4E cell transplantation after I/R injury
(a) The measurement of plasma creatinine concentration demonstrated a significantly lower
creatinine level in transplanted mice 2–3 days after I/R renal injury. The shaded line shows the
baseline plasma creatinine level in normal mice (0.24 ± 0.07 mg per 100 ml). (b) Representative
images of Ki-67 and TUNEL stainings in control and 4E-transplanted mouse kidneys. (c)
Quantitative analysis of Ki-67 and TUNEL-positive cells in the kidney sections 3 days after
ischemic injury. Original magnification was × 400. *P < 0.05 vs non-transplanted control mice
with I/R injury, N, area of necrosis. n = 6 in each group, values are mean ± s.e.m.
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Figure 7. Microvascular rarefaction in post-ischemic kidneys
Representative images of CD31 staining in control (a) and 4E-injected (b) mice on day 3 after
I/R injury. (c) To quantify vascular dropout in post-ischemic kidneys, microvascular
rarefaction index was calculated as detailed in Materials and Methods. Three days post-
ischemia microvasculature was significantly preserved by the administration of 4E cells
compared with un-treated kidneys. At later times, 15 and 30 days post-ischemia, the differences
in rarefaction index disappeared. (d) 4E-Transplanted mouse kidneys showed a fivefold
increase in renal VEGF expression at 3 days after I/R injury. In contrast, plasma VEGF level
did not show any significant difference between the two groups. Original magnification was
× 400. *P < 0.05 vs control. n = 4 in each group, values are mean ± s.e.m.
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